Inhibition of peripheral blood lymphocyte apoptosis by soluble fas ligand in patients with hepatocellular carcinoma.

Nakamoto,Y; Kaneko,S; Buttner,S W; Matsushita,E; Kobayashi,K

doi:10.3892/or.6.4.733

Inhibition of peripheral blood lymphocyte apoptosis by soluble fas ligand in patients with hepatocellular carcinoma.

Authors:
- Y Nakamoto
- S Kaneko
- S W Buttner
- E Matsushita
- K Kobayashi
View Affiliations

Affiliations: First Department of Internal Medicine, Faculty of Medicine, Kanazawa University, Kanazawa, Japan.
Published online on: July 1, 1999 https://doi.org/10.3892/or.6.4.733
Pages: 733-742

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We monitored apoptosis of peripheral blood lymphocytes (PBL) obtained from patients with various degrees of chronic viral hepatitis, including hepatocellular carcinoma (HCC), in vitro and quantitated the serum levels of soluble Fas ligand (FasL) by ELISA. There was no difference in mean percent PBL mortality. However, in HCC patients, the variance was significantly high (P<0.05), and, unexpectedly, a negative association was found between the PBL mortality and the serum soluble FasL levels (P=0.035). These results suggest the inhibitory effect of serum soluble FasL on apoptosis of PBL, which may explain the induction of immunological abnormalities with the development of HCC.